We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Bisbenzimidazoles: Anticancer Vacuolar (H⁺)-ATPase Inhibitors

*Renukadevi Patil, Olivia Powrozek, Binod Kumar,
William Seibel, Kenneth Beaman, Gulam Waris,
Neelam Sharma-Walia and Shivaputra Patil*

Abstract

Small molecule chemotherapeutic agents such as Imatinib, Gefitinib, and Erlotinib have played a significant role in the treatment of cancer. Although the unprecedented progress has been achieved in cancer treatment with these targeted agents, there is a strong demand for the development of selective and highly efficacious cancer drugs. V-ATPases are emerging as important target for the identification of novel therapeutic agents for cancer. Our screening and drug discovery processes have identified the bisbenzimidazole derivative (**RP-15**) as a potent anticancer V-ATPase inhibitor. In the present study, bisbenzimidazoles (compound-25, **RP-11** and **RP-15**) have been tested for proton-pump inhibition activity in human hepatoma cell line (Huh7.5). **RP-15** displayed comparable proton-pump inhibition activity to the standard Bafilomycin A1. We examined the antiproliferative activity of these analogs in two highly invasive and metastatic inflammatory breast cancer (IBC) cell lines (SUM 149PT and SUM190PT) along with Huh7.5. The compound-25 (SUM190PT: IC₅₀ = 0.43±0.11 μM) and its structural analog **RP-11** (SUM190PT: IC₅₀ = 0.49±0.09 μM) have shown significant inhibition toward IBC cell lines. Additionally, **RP-11** and **RP-15** have demonstrated very good cytotoxicity toward the majority of cancer cell lines in the NCI 60 cell line panel.

Keywords: bisbenzimidazoles, anticancer, V-ATPase, proton-pump, inhibitors

1. Introduction

Since Paul Ehrlich's introduction of the concept of chemotherapy, development of chemotherapeutic agents for cancer over the past several decades has seen marvelous records of accomplishments [1, 2]. Cancer is one of the major health problems globally and is second leading cause of death in the USA [3, 4]. Cancer is a very complex disease and our understanding towards it has been advanced tremendously over the last six decades since the first human cancer cell line HeLa identified in 1952 [5]. Over the past few years, the search for new anticancer drugs has changed dramatically. Advances in the molecular nature of drug action, new technology and more recently market considerations have produced new approaches to cancer drug discovery [6]. Recent advances in molecular biology, high throughput screening

(HTS), computer-aided drug design (CADD), and combinatorial chemistry technologies have allowed a combination of both knowledge around the drug receptor and large library screening to be used for anticancer drug discovery today [7–10].

As the understanding of human biology and new technologies progressed, the discovery and development process moved from a random pattern to a more predictable one. The development of a molecularly targeted anticancer drug has gained importance in recent years [11]. One of the important small molecule targeted therapy, Imatinib (Gleevec®), a tyrosine kinase inhibitor, achieved incredible advancement in cancer treatment [12–14]. Imatinib's success stimulated the scientists to develop variety of targeted anticancer agents including Gefitinib (Iressa™) and Erlotinib (Terceva®) for the treatment of different types of cancer patients (**Figure 1**). Targeted agents represented significant developments in cancer treatment and have increased the life expectancy of patients [15–18]. Despite the unprecedented progress achieved, the anticancer drug discovery research remains highly challenging and there is strong demand for the development of highly efficacious and safe anticancer drugs which can overcome cancer metastasis, and drug resistance.

Recent studies suggest that an acidic microenvironment in the tumor is responsible for cancer development, progression, and metastasis. Novel drugs that specifically target the mechanism by which V-ATPase lowers the pH of the tumor microenvironment are essential for cancer chemotherapy. Among the key regulators of the tumor, acidic microenvironment V-ATPases plays an important role in the regulation of the pH gradient. V-ATPases play a vital role in the maintenance of the tumor acidic microenvironment and are overexpressed in many types of metastatic cancers including breast cancer. V-ATPases are functionally expressed in plasma membranes of tumor cells and they have specialized functions in metastasis [19]. Recent research has demonstrated that the preferential expression of V-ATPase at the cell surface is important for the acquisition of invasiveness and the metastasis of breast cancer cells [19]. Therefore, V-ATPase is a potential target to investigate for metastatic breast cancer therapy. Discovery and development of easily synthesized,

Figure 1.
Molecularly targeted clinically successful chemotherapeutic agents.

cost-effective, and potent small molecule drugs targeting V-ATPase are needed to evaluate the therapeutic potential of V-ATPase inhibitors in metastatic breast cancer.

The V-ATPases are a family of ATP-driven proton pumps that couple ATP hydrolysis with translocation of protons across membranes. The V-ATPase proton pump is a macromolecular complex composed of at least 14 subunits organized into two functional domains, V1 is responsible for ATP hydrolysis and V0 provides the transmembrane proton channel [20–23]. The V-ATPases have been associated with cancer invasion, metastasis and drug resistance [19, 24–27]. Several pre-clinical studies have reported the anticancer effects of V-ATPase inhibitors [28–32]. V-ATPase inhibitors will be beneficial for cancer patients given either in combination with cytotoxic agents or dual-acting (anticancer and V-ATPase inhibitor) agents. Thus, V-ATPases are emerging as an important target for the identification of potential novel chemotherapeutic agents. Despite the clear involvement of V-ATPases in cancer, to date, therapeutic use of V-ATPase targeting small molecules have not reached the clinic. Natural products macrolide antibiotics, such as bafilomycin and concanamycin, potentially inhibit V-ATPases [33–37] (**Figure 2**), but their use is complicated by non-specific effects on other targets. Moreover, these molecules have been difficult to synthesize in large quantities. Despite huge efforts by both academic and pharmaceutical industry medicinal chemists, development of useful V-ATPase inhibitors has been limited because of the complicated chemical structures of existing natural inhibitors.

We have been actively involved in the design and development of novel small molecular agents for different types of cancers. Past few years, we have reported the chromene-, chromenopyridine-, and imidazoquinoline-based pharmacophores as initial lead anticancer drug candidates through screening and drug development process [38–40]. Notably, we have identified the highly potent microtubule targeting anticancer agent (**SP-6-27**) for ovarian cancer [41]. Since then our laboratory has been active in identifying anticancer agents with different mechanisms of action. In continuation of our drug discovery research, we recently initiated a collaborative effort on the V-ATPases as anti-cancer targets. Successful identification of new lead small molecule drugs for ovarian cancer by screening and drug development processes [41] inspired us to screen the library of compounds based on the literature of known V-ATPase inhibitors. We identified the bisbenzimidazole scaffold from screening process. Bisbenzimidazoles are nitrogen heterocycles with wide spectrum of biological activities. We

Figure 2.
 Natural potent V-ATPase inhibitors.

reported the focused set of bisbenzimidazoles as anticancer V-ATPase agents (**Figure 3**) [42]. Bisbenzimidazole derivatives (**RP-3–RP-15**) have been screened in selected human breast cancer (MDA-MB-231, MDA-MB-468, MCF-7) and ovarian cancer (cisplatin-sensitive A2780, cisplatin-resistant Cis-A2780 and PA-1) cell lines. Among this small set of bisbenzimidazoles, **RP-15** demonstrated high potency towards the epidermal growth factor receptor (EGFR) over expressed triple negative breast cancer (TNBC) cell line, MDA-MB-468 ($IC_{50} = 0.04 \pm 0.02 \mu M$). Very interestingly, **RP-15** is not toxic to normal breast epithelial cells. It is nearly 40 times less toxic in the normal breast epithelial cell line, MCF10A ($IC_{50} = 1.62 \pm 0.14 \mu M$). Furthermore, the bisbenzimidazole derivatives (Compound-25, **RP-11** and **RP-15**) have demonstrated encouraging proton pump inhibition activity in MDA-MB-231. In particular our most efficacious anticancer analog **RP-15** has shown comparable proton pump inhibition activity to standard agent Bafilomycin A1.

In the present study, we selected and screened top two bisbenzimidazole derivatives (**RP-11** and **RP-15**) along with initial hit (compound 25) for proton pump inhibition activity in human hepatoma cells, Huh7.5 using pH indicator Lysosensor Yellow/Blue DND-160. These compounds have also been screened for their antiproliferative activity using BrDU incorporation assay in selected inflammatory breast cancer (IBC) cell lines (SUM149PT and SUM190PT) along with Huh7.5 human hepatoma cancer cell line. Additionally, **RP-11** and

Figure 3.
Bisbenzimidazoles derivatives.

RP-15 have been tested in NCI Developmental Therapeutics Program (DTP) nine major (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) 60 human cancer cell lines.

2. Methods

2.1 Chemical synthesis

We recently reported the synthesis and detailed characterization of all these new bisbenzimidazoles [42]. In brief, we developed a fast and efficient synthetic one pot procedure to prepare all these analogs (**RP-3–RP-15**). Condensation of 4-(6-(4-methylpiperazin-1-yl)-1H, 30H-[2, 50-bibenzo [d]imidazol]-20-yl) phenol with substituted alkyl halides in the presence of cesium carbonate in dimethyl formamide (DMF). For the more detailed synthesis and spectral and analytical characterization of all these compounds please see Ref. [42].

2.2 Proton pump inhibition activity in human hepatoma (Huh7.5) cell line

We used Huh7.5 cell line for proton pump activity. Briefly, the Huh7.5 cells were cultured in DMEM media supplemented with 10% serum to a confluency of 80%. The Huh7.5 cells were treated with the compounds (Compound-25, **RP-11** and **RP-15**) at a concentration of 12 µM for 20 minutes followed by incubation with Lysosensor Yellow/Blue DND-160 (10 µM) for 10 minutes at 37°C. The cells were visualized under the microscope.

2.3 Antiproliferative activity

Cell proliferation ELISA BrdU colorimetric (assay no. 11647229001; Roche, Basel, Switzerland) was used to quantify cell proliferation by the measurement of BrdU incorporated during DNA synthesis. Cells from a 90% confluent T-25 flask were seeded 100 µL/well of 96-well plates and incubated overnight. Dimethyl Sulfoxide (DMSO) stock solutions of the compounds (Compound-25, **RP-11** and **RP-15**) were diluted in pure F-12 media and exposed to different concentrations for 24 and 48 hours. Each concentration and controls were done in triplicates. The mean ± standard deviation (S.D.) was calculated and shown on the graph with untreated cells serving as a negative control, 20 minutes after adding the substrate, the absorbance was read at 370 nm. The compound concentration that inhibited cell growth by 50% of the untreated control (IC₅₀) was calculated from the dose response curves constructed by normalizing the data to percentages based of the negative control and a nonlinear regression analysis in GraphPad Prism Software 7 (GraphPad Software, San Diego, CA, USA). For the Huh7.5 cell line we used CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, WI, USA).

2.4 The NCI 60 cell lines *in vitro* screening

The bisbenzimidazoles (**RP-11** and **RP-15**) have been tested for growth inhibition against 60 human cancer cell lines from the NCI's anticancer screening program. The NCI's screening procedure has been given in detail elsewhere [43–47] and presently DTP uses the sulforhodamine B (SRB) assay.

3. Results and discussion

Inhibition of V-ATPase has shown the link between cell biophysical properties and proliferative signaling selectively in malignant hepatocellular carcinoma (HCC) cells, which provides a new strategy to combat HCC [48]. HCC is the third most common cause of cancer-related deaths worldwide. HCC is accounting for almost 90% of primary malignant hepatic tumors in adults. In continuation of our work on V-ATPase inhibition, we used Huh7.5 cells for the proton pump inhibition activity. We have performed proton pump inhibitory activity of selected bisbenzimidazole derivatives (Compound-25, **RP-11** and **RP-15**) in Huh7.5 cells using Lysosensor Yellow/Blue DND-160 protocol [49]. The DND-160 is a pH indicator and cellular compartments with acidic pH elicit yellow fluorescence when stained, while the destabilized compartments with higher pH elicit blue fluorescence.

The compound **RP-15** displayed maximum inhibition of the proton-pump activity of V-ATPase followed by compound-25 and **RP-11**. The untreated cells showed the strong intensity of yellow fluorescence (converted to pseudo-green in the **Figure 4A**) while the cells treated with bisbenzimidazoles (Compound-25, **RP-11** and **RP-15**) showed the strong intensity of blue fluorescence representing varying degree of destabilization of pH due to impaired vacuolar ATPase activity (**Figure 4A** and **B**). Additionally, these compounds have been tested for their cytotoxicity towards Huh7.5 cells using the CellTiter-Glo Luminescent Cell Viability Assay. The IC_{50} were calculated based on the results obtained for these compounds treated for 24 hours only for Huh7.5 cells compared to breast and ovarian cancer cell lines where we treated all test compounds for 48 hours. Bisbenzimidazoles, **RP-11** and **RP-15** have demonstrated very moderate antiproliferative activity towards Huh7.5 cells for 24 hours (**Table 1**).

High potency of bisbenzimidazole analog (**RP-15**) against the EGFR over expressed TNBC cell line (MDA-MB-468) inspired us to explore the selected bisbenzimidazoles in other breast cancer cell lines for anticancer activity. We selected two IBC cell lines (triple negative SUM149PT and Het2 positive SUM190PT) for the *in vitro* screening process [50]. Both SUM149 and SUM190 cell lines have been established from primary IBC tumors. IBC is one of the highly invasive, metastatic and lethal variant of human breast cancer. Development of therapeutic targets and agents for IBC is still in very early stage and it represents an opportunity for medicinal chemists to develop novel (pre) clinical drug candidates.

In vitro screening of the bisbenzimidazoles (Compound-25, **RP-11** and **RP-15**) towards these inflammatory cell lines has shown encouraging results (**Figure 5** and **Table 1**). Very interestingly our initial hit, compound-25 (SUM149PT: $IC_{50} = 0.80 \pm 0.08 \mu M$; SUM190PT: $IC_{50} = 0.43 \pm 0.11 \mu M$) and its structural analog **RP-11** (SUM149PT: $IC_{50} = 0.91 \pm 0.15 \mu M$; SUM190PT: $IC_{50} = 0.49 \pm 0.09 \mu M$) have shown very good inhibition, whereas our TNBC lead **RP-15** (SUM149PT: $IC_{50} = 1.77 \pm 0.08 \mu M$; SUM190PT: $IC_{50} = 2.08 \pm 0.56 \mu M$) has demonstrated moderate inhibition towards these IBC cell lines. The high potency shown by compound-25 and **RP-11** towards IBC has given us more insights to develop new anticancer agents for it and we plan to explore the structure-activity relationship (SAR) studies based on the bisbenzimidazole scaffold in very near future.

The Development Therapeutic Program (DTP) of the National Cancer Institute's 60 human tumor cell lines screen was developed as an *in vitro* drug discovery tool. We submitted both compounds (**RP-11** and **RP-15**) to the NCI Developmental Therapeutics Program (DTP) anticancer drug screen. Both of them have been first tested for three cell lines (MCF-7 breast cancer; NCI-H460 large-cell lung cancer; SF-268 glioma) to advance to the 60 cell line screen. This pre-screen process eliminates the inactive compounds but preserves active agents for 60 cell line screening.

Figure 4.
(A) Staining of acidic compartments: Yellow signal (converted to pseudo-green) represents acidic pH, while the blue color represents slightly acidic to neutral pH. Huh75 cells were treated with the compounds (Compound-25, RP-11 and RP-15) at a concentration of 12 μ M and standard Bafilomycin A1 at concentration of 2 μ M for 20 minutes followed by incubation with Lysosensor Yellow/Blue DND-160 (10 μ M) for 10 minutes at 37°C. The cells were visualized under the microscope. The DND-160 is a pH indicator and cellular compartments with acidic pH elicit yellow fluorescence when stained, while the destabilized compartments with higher pH elicit blue fluorescence. The expected yellow color showed yellowish green of the filters available in the microscope. (B) Fold change in overall acidification of Huh75 cells upon treatment with bisbenzimidazoles (Compound-25, RP-11 and RP-15) along with positive control BafilomycinA1.

Both compounds have been advanced to 60 cell lines representing nine major cancers (leukemia, non-small cell lung, central nervous system, colon, melanoma, ovarian, renal, prostate, and breast). Compounds have been tested over a broad range of concentrations against every cell line in the panel (five 10 fold dilutions starting

Compd.	IC ₅₀ ± SD (μM)					
	SUM149PT	SUM190PT	MDA-MB-468 [‡]	MCF10A [‡]	Cis-A2780 [‡]	Huh7.5 [†]
C-25	0.80 ± 0.08	0.43 ± 0.11	0.72 ± 0.08	1.14 ± 0.13	3.95 ± 0.33	17.1 ± 0.85
RP-11	0.91 ± 0.15	0.49 ± 0.09	0.56 ± 0.05	1.55 ± 0.04	3.03 ± 0.18	17.0 ± 0.78
RP-15	1.77 ± 0.08	2.08 ± 0.56	0.04 ± 0.02	1.62 ± 0.14	1.34 ± 0.14	16.4 ± 0.65
Baf A1	ND	ND	ND	0.036 ± 0.04	0.008 ± 0.01	ND

ND: not determined.

[‡]Data from Ref. [42].

[†]The IC₅₀ is calculated based on the results obtained from 24 hours drug treatment only.

Table 1.
Half maximal inhibitory concentration of novel bisbenzimidazole analogs in different cancer cell lines.

Figure 5.
The cell viability (%) of breast cancer cell lines (SUM190PT and SUM149PT) following the exposure of various concentrations of bisbenzimidazoles (Compound-25, RP-11 and RP-15) for 48 hours.

Figure 6.
Dose response curves derived from screening of compound **RP-11** (NSC: D-800436) in 60 cell line screen using nine major human cancer cell lines (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer).

Figure 7. The mean graph representation of antitumor effects of compound **RP-11** (NSC: D-800436). The GI_{50} (50% of growth inhibition), TGI (total growth inhibition) and LC_{50} (50% of lethal concentration) mean graphs are derived from the dose response curves using **Figure 6** from the initial screening.

from 10^{-4} M concentration). **Figures 6 and 8** describe the dose response curves for compounds **RP-11** (NSC: D-800436) and **RP-15** (NSC: D-800437) respectively. From these dose response curves three end points were calculated (GI_{50} : 50% of growth inhibition; TGI: total growth inhibition; LC_{50} : 50% of lethal concentration). **Figures 7 and 9** demonstrate mean graph patterns for compound **RP-11** and **RP-15** respectively. Mean graphs are created for GI_{50} , TGI, and LC_{50} by plotting positive and negative values termed as deltas generated from dose response curves. More sensitive cell lines are displayed as bars that project to the right of the mean, whereas the less sensitive cell lines are displayed with bars projected to the left. The length of each bar is proportional to the relative sensitivity of the agent with the mean determination.

Both bisbenzimidazole analogs, **RP-11** and **RP-15** demonstrated very good cytotoxicity towards the majority of cancer cell lines in the 60 cell line panel. Compound **RP-11** displayed growth inhibition and total growth inhibition to low micromolar range and is moderate towards LC_{50} for MCF7 (GI_{50} : 0.32 μ M, TGI: 11.8 μ M and LC_{50} : 88.7 μ M), MDA-MB-468 (GI_{50} : 1.42 μ M, TGI: 4.16 μ M and LC_{50} : 28.2 μ M) and MDA-MB-231 (GI_{50} : 2.25 μ M, TGI: 6.49 μ M and LC_{50} : 60.4 μ M). Interestingly, it showed low micromolar range effects against other cell lines such as SR (GI_{50} : 0.50 μ M); NCI-H522 (GI_{50} : 0.34 μ M); COLO 205 (GI_{50} : 0.37 μ M); SF-268 (GI_{50} : 0.58 μ M); OVCAR-3 (GI_{50} : 0.62 μ M) and MDA-MB-435 (GI_{50} : 0.62 μ M) (**Table 2**). Compound **RP-15** shows similar behavior as **RP-11**. Compound **RP-15** exhibited GI_{50} : 1.91 μ M, TGI: 4.13 μ M and LC_{50} : 8.91 μ M for the MDA-MB-468 cell line, whereas a similar trend is observed for the MDA-MB-231 cell line (GI_{50} : 2.85 μ M, TGI: 5.83 μ M and LC_{50} : 21.3 μ M). Similarly, low micromolar growth inhibition was observed for other cell lines such as MDA-MB-435 (GI_{50} : 1.97 μ M), RXF

Figure 8. Dose response curves derived from screening of compound **RP-15** (NSC: D-800437) in 60 cell line screen using nine major human cancer cell lines (leukemia, non small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer).

Figure 9. The mean graph representation of antitumor effects of compound RP-15 (NSC: D-800437). The GI₅₀ (50% of growth inhibition), TGI (total growth inhibition) and LC₅₀ (50% of lethal concentration) mean graphs are derived from the dose response curves using **Figure 8** from the initial screening.

Cell line	RP-11 (μM)			RP-15 (μM)			Cell line	RP-11 (μM)			RP-15 (μM)		
	GI ₅₀	TGI	LC ₅₀	GI ₅₀	TGI	LC ₅₀		GI ₅₀	TGI	LC ₅₀	GI ₅₀	TGI	LC ₅₀
Leukemia							MDA-MB-435	0.62	2.14	5.66	1.97	3.99	8.10
CCRF-CEM	1.02	>100	>100	2.72	7.34	92.8	SK-MEL-2	1.64	3.59	7.89	19.7	3.5	75.0
HL-60(TB)	1.62	91.8	>100	4.71	29.1	100	SK-MEL-28	0.478	2.21	6.08	3.03	9.43	40.1
K-562	0.91	>100	>100	2.24	4.45	–	SK-MEL-5	0.351	1.88	5.06	12.7	27.6	59.8
MOLT-4	2.81	>100	>100	3.12	10.7	100	UACC-257	1.71	5.92	35.9	20.5	38.3	71.4
RPMI-8226	4.11	35.5	>100	2.86	7.44	100	UACC-62	0.36	2.02	6.37	17.3	40.1	93.1
SR	0.50	21.9	>100	2.90	8.05	100	Ovarian cancer						
Non-small cell Lung							IGROV1	1.71	4.81	>100	7.69	31.6	100
A549/ATCC	8.05	35.2	>100	4.69	17.7	88.6	OVCAR-3	0.62	3.13	57.0	5.22	16.8	46.7
EKVX	6.56	46.3	>100	4.67	21.4	81.4	OVCAR-4	0.313	2.99	>100	10.1	25.5	64.0
HOP-62	1.56	14.5	>100	7.10	26.8	89.0	OVCAR-5	3.59	9.96	>100	2.96	9.96	33.8
HOP-92	2.16	9.71	>100	14.3	33.2	77.0	OVCAR-8	0.931	23.4	>100	4.69	18.6	81.5
NCI-H226	1.44	–	>100	23.8	52.2	100	NCI/ADR-RES	>100	>100	>100	35.7	>100	>100
NCI-H23	1.21	5.09	57.2	15.1	33.0	71.9	SK-OV-3	2.70	15.6	>100	18.0	36.0	72.0

Cell line	RP-11 (μM)			RP-15 (μM)			Cell line	RP-11 (μM)			RP-15 (μM)		
	GI ₅₀	TGI	LC ₅₀	GI ₅₀	TGI	LC ₅₀		GI ₅₀	TGI	LC ₅₀	GI ₅₀	TGI	LC ₅₀
NCI-H322M	3.07	9.93	>100	11.6	23.8	48.8		Renal cancer					
NCI-H460	3.63	14.7	>100	2.12	3.98	7.44	786.0	1.64	3.81	8.86	2.70	8.33	>100
NCI-H522	0.34	2.36	>100	13.6	38.1	>100	A498	1.21	3.39	9.54	17.5	35.1	70.3
Colon cancer							ACHN	10.7	>100	>100	9.20	22.8	54.2
COLO 205	0.37	3.05	>100	12.9	30.0	69.8	CAKI-1	2.25	>100	>100	4.15	15.7	47.2
HCC-2998	1.78	3.78	8.03	5.06	18.5	56.7	RXF 393	1.80	3.63	7.32	1.91	3.84	–
HCT-116	0.36	2.46	>100	1.82	3.44	–	SN12C	1.42	11.8	>100	4.00	15.4	66.2
HCT-15	38.7	>100	>100	12.1	28.1	65.4	TK-10	4.74	40.2	>100	18.2	38.8	83.0
HT29	0.58	>100	>100	1.78	4.07	9.30	UO-31	29.4	>100	>100	21.3	41.8	82.3
KM12	2.58	14.3	65.4	1.91	4.20	9.26		Prostate cancer					
SW-620	0.90	10.2	36.5	2.12	3.96	7.37	PC-3	2.19	24.5	>100	2.63	5.81	21.8
CNS cancer							DU-145	1.13	9.59	>100	1.83	3.40	6.29
SF-268	0.58	5.66	62.9	6.58	25.4	81.0		Breast cancer					
SF-295	1.38	15.7	>100	2.34	6.22	48.4	MCF7	0.32	11.8	88.7	1.85	3.96	–
SF-539	1.22	2.83	6.59	11.5	26.1	59.5	MDA-MB-231/ATCC	2.25	6.49	60.4	2.85	5.83	21.3
SNB-19	1.87	10.5	52.9	2.15	4.09	7.79	HS578T	2.94	15.9	>100	10.5	37.1	>100
SNB-75	0.49	3.14	15.2	3.46	18.0	47.0	BT-549	1.76	3.96	8.91	17.5	40.1	91.7
U251	0.66	10.2	36.5	2.16	3.81	6.74	T-47D	1.00	9.09	>100	14.2	41.1	>100
Melanoma							MDA-MB-468	1.42	4.16	28.2	1.91	4.13	8.91
LOX IMVI	0.85	2.83	8.66	1.84	3.67	–							
MALME-3 M	0.16	1.55	4.61	12.2	27.2	60.4							
M14	0.45	2.50	9.80	2.39	6.53	40.0							

Table 2.
The NCI 60 cancer cell line screening results.

393 (GI₅₀: 1.91 μM), HT29 (GI₅₀: 1.78 μM), LOXIMVI (GI₅₀: 1.84 μM), DU-145 (GI₅₀: 1.83 μM) and KM12 (GI₅₀: 1.91 μM) (**Table 2**). Overall, the NCI 60 cell line results are encouraging for both new bisbenzimidazole derivatives.

4. Conclusions and future directions

In summary, our screening and drug discovery processes have identified the bisbenzimidazole (**RP-15**) as a potent anticancer V-ATPase inhibitor for TNBC and **RP-11** as initial lead for the IBC. The compound **RP-15** showed maximum inhibition of the proton-pump activity which is comparable to our standard agent Bafilomycin A1. The *in vitro* antiproliferative activity of these bisbenzimidazole analogs (Compound-25, **RP-11** and **RP-15**) towards IBC cell lines revealed that compound-25 and its structural analog **RP-11** could be possibly considered for further exploration in other IBC cell lines. Bisbenzimidazoles **RP-11** (NSC: D-800436) and **RP-15** (NSC: D-800437) have demonstrated very good cytotoxicity towards the majority of cancer cell lines in the NCI 60 cell line panel. Overall, our research identified efficacious and selective anticancer V-ATPase inhibitors for TNBC and

IBC. We will continue to explore the SAR with this exciting pharmacophore to identify the highly selective and potent V-ATPase inhibitors which will ultimately lead to the generation of investigational new drug (IND) candidates for the clinical testing in TNBC and IBC patients.

Acknowledgements

The screening of **RP-11** and **RP-15** against 60 human cancer cell lines of NCI's development therapeutic program (DTP) is greatly acknowledged. Rosalind Franklin University of Medicine and Science University start-up grant to NSW. National Institute of Health grant (DK106244) to GW.

Conflict of interest

The authors declare no conflict of interest, financial or otherwise.

Author details

Renukadevi Patil¹, Olivia Powrozek², Binod Kumar², William Seibel³, Kenneth Beaman², Gulam Waris², Neelam Sharma-Walia² and Shivaputra Patil^{1*}

¹ Pharmaceutical Sciences Department, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

² Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

³ Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

*Address all correspondence to: shivaputra.patil@rosalindfranklin.edu

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] Kaufmann SH. Paul Ehrlich: Founder of chemotherapy. *Nature Reviews. Drug Discovery*. 2008;7(5):373-373. DOI: 10.1038/nrd2582
- [2] Xu J, Mao W. Overview of research and development for anticancer drugs. *Journal of Cancer Therapy*. 2016;7:762-772. DOI: 10.4236/jct.2016.710077
- [3] Siegel RL, Miller KD, Jemal A. Cancer statistics. *A Cancer Journal for Clinicians*. 2017;67:7-30. DOI: 10.3322/caac.21387
- [4] Noone AM, Howlander N, Krapcho M, Miller D, Brest A, Yu M, et al., editors. *SEER Cancer Statistics Review*. Bethesda, MD: National Cancer Institute; 1975-2015. Available from: https://seer.cancer.gov/csr/1975_2015/
- [5] Gey GO, Coffman WD, Kubicek MT. Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. *Cancer Research*. 1952;12:264-265
- [6] Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: Origins, implications, barriers, solutions. *Nature Reviews. Clinical Oncology*. 2017;14(6):381-390. DOI: 10.1038/nrclinonc.2017.31
- [7] Belfield GP, Delaney SJ. The impact of molecular biology on drug discovery. *Biochemical Society Transactions*. 2006;34(2):313-316. DOI: 10.1042/BST20060313
- [8] Liu B, Li S, Hu J. Technological advances in high-throughput screening. *American Journal of Pharmacogenomics*. 2004;4(4):263-276. DOI: 10.2165/00129785-200404040-00006
- [9] Ooms F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. *Current Medicinal Chemistry*. 2000;7:141-158. DOI: 10.2174/0929867003375317
- [10] Hogan JC Jr. Combinatorial chemistry in drug discovery. *Nature Biotechnology*. 1997;15:328-330. DOI: 10.1038/nbt0497-328
- [11] Aggarwal S. Targeted cancer therapies. *Nature Reviews. Drug Discovery*. 2010;9(6):427-428. DOI: 10.1038/nrd3186
- [12] Baselga J. Targeting tyrosine kinases in cancer: The second wave. *Science*. 2006;312:1175-1178. DOI: 10.1126/science.1125951
- [13] Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. *Chemotherapy Research and Practice*. 2014;2014:357027. DOI: 10.1155/2014/357027
- [14] Jones RL, Judson IR. The development and application of imatinib. *Expert Opinion on Drug Safety*. 2005;4(2):183-191. DOI: 10.1517/14740338.4.2.183
- [15] Herbst RS, Fukuoka M, Baselga J. Gefitinib—A novel targeted approach to treating cancer. *Nature Reviews. Cancer*. 2004;4(12):956-965. DOI: 10.1038/nrc1506
- [16] Sanford M, Scott LJ. Gefitinib: A review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. *Drugs*. 2009;69(16):2303-2328. DOI: 10.2165/10489100-000000000-00000
- [17] Dowell J, Minna JD, Kirkpatrick P. Erlotinib hydrochloride. *Nature Reviews. Drug Discovery*. 2005;4(1):13-14. DOI: 10.1038/nrd1612
- [18] Blackhall FH, Rehman S, Thatcher N. Erlotinib in non-small cell lung

cancer: A review. *Expert Opinion on Pharmacotherapy*. 2005;**6**(6):995-1002. DOI: 10.1517/14656566.6.6.995

[19] Sennoune SR, Bakunts K, Martínez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H⁺-ATPase in human breast cancer cells with distinct metastatic potential: Distribution and functional activity. *American Journal of Physiology. Cell Physiology*. 2004;**286**(6):C1443-C1452. DOI: 10.1152/ajpcell.00407.2003

[20] Nishi T, Forgac M. The vacuolar (H⁺)-ATPases—nature's most versatile proton pumps. *Nature Reviews. Molecular Cell Biology*. 2002;**3**(2): 94-103. DOI: 10.1038/nrm729

[21] Finbow ME, Harrison MA. The vacuolar H⁺-ATPase: A universal proton pump of eukaryotes. *The Biochemical Journal*. 1997;**324**(Pt 3):697-712. DOI: 10.1042/bj3240697

[22] Yokoyama K, Imamura H. Rotation, structure, and classification of prokaryotic V-ATPase. *Journal of Bioenergetics and Biomembranes*. 2005;**37**(6):405-410. DOI: 10.1007/s10863-005-9480-1

[23] Wang Y, Cipriano DJ, Forgac M. Arrangement of subunits in the proteolipid ring of the V-ATPase. *The Journal of Biological Chemistry*. 2007;**282**(47):34058-34065. DOI: 10.1074/jbc.M704331200

[24] Fais S, De Mito A, You H, Qin W. Targeting vacuolar H⁺-ATPases as a new strategy against cancer. *Cancer Research*. 2007;**67**(22):10627-10630. DOI: 10.1158/0008-5472.CAN-07-1805

[25] Sennoune SR, Luo D, Martinez-Zaguilan R. Plasmalemmal vacuolar-type H⁺-ATPase in cancer biology. *Cell Biochemistry and Biophysics*. 2004;**40**(2):185-206. DOI: 10.1385/CBB:40:2:185

[26] Capecci J, Forgac M. The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells. *The Journal of Biological Chemistry*. 2013;**288**(45):32731-32741. DOI: 10.1074/jbc.M113.503771

[27] Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. *Cancer Research*. 2006;**66**(13):6699-6707. DOI: 10.1158/0008-5472.CAN-06-0983

[28] Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. *Journal of Pathology*. 1998;**185**:324-330. DOI: 10.1002/(SICI)1096-9896(199807)185:3<324::AID-PATH72>3.0.CO;2-9

[29] Lee JC, Lee CH, Su CL, Huang CW, Liu HS, Lin CN, et al. Justicidin a decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cells. *Carcinogenesis*. 2005;**26**:1716-1730. DOI: 10.1093/carcin/bgi133

[30] Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, Kubisch-Dohmen R, Liebl J, et al. Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. *Cancer Research*. 2015;**75**: 2863-2874. DOI: 10.1158/0008-5472.CAN-14-2097

[31] Nakashima S, Hiraku Y, Tada-Oikawa S, Hishita T, Gabazza EC, Tamaki S, et al. Vacuolar H⁺-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. *Journal of Biochemistry*. 2003;**134**:359-364. DOI: 10.1093/jb/mvg153

[32] Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti

- vacuolar-ATPases drugs: A novel anticancer strategy. *Journal of Experimental & Clinical Cancer Research*. 2010;**29**:44. DOI: 10.1186/1756-9966-29-44
- [33] Bowman EJ, Graham LA, Stevens TH, Bowman BJ. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from *Neurospora crassa* and *Saccharomyces cerevisiae*. *The Journal of Biological Chemistry*. 2004;**279**(32):33131-33138. DOI: 10.1074/jbc.M404638200
- [34] Scheidt KA, Bannister TD, Tasaka A, Wendt MD, Savall BM, Fegley GJ, et al. Total synthesis of (–)-bafilomycin A1. *Journal of the American Chemical Society*. 2002;**124**(24):6981-6990. DOI: 10.1021/ja017885e
- [35] Lim JH, Park JW, Kim MS, Park SK, Johnson RS, Chun YS. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1 α . *Molecular Pharmacology*. 2006;**70**(6):1856-1865. DOI: 10.1124/mol.106.028076
- [36] Hayashi Y, Katayama K, Togawa T, Kimura T, Yamaguchi A. Effects of bafilomycin A1, a vacuolar type H⁺ ATPase inhibitor, on the thermosensitivity of a human pancreatic cancer cell line. *International Journal of Hyperthermia*. 2006;**22**(4):275-285. DOI: 10.1080/02656730600708049
- [37] Huss M, Ingenhorst G, König S, Gassel M, Dröse S, Zeeck A, et al. Concanamycin a, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. *The Journal of Biological Chemistry*. 2002;**277**(43):40544-40548. DOI: 10.1074/jbc.M207345200
- [38] Patil SA, Wang J, Li XS, Chen J, Jones TS, Hosni-Ahmed A, et al. New substituted 4H-chromenes as anticancer agents. *Bioorganic & Medicinal Chemistry Letters*. 2012;**22**(13):4458-4461. DOI: 10.1016/j.bmcl.2012.04.074
- [39] Patil R, Ghosh A, Sun Cao P, Sommer RD, Grice KA, Waris G, et al. Novel 5-arylthio-5H-chromenopyridines as a new class of anti-fibrotic agents. *Bioorganic & Medicinal Chemistry Letters*. 2017;**27**(5):1129-1135. DOI: 10.1016/j.bmcl.2017.01.089
- [40] Patil SA, Pfeffer SR, Seibel WL, Pfeffer LM, Miller DD. Identification of imidazoquinoline derivatives as potent antiglioma agents. *Medicinal Chemistry*. 2015;**11**(4):400-406. DOI: 10.2174/1573406410666140914162701
- [41] Kulshrestha A, Katara GK, Ibrahim SA, Patil R, Patil SA, Beaman KD. Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. *Oncotarget*. 2017;**8**(40):67017-67028. DOI: 10.18632/oncotarget.17549
- [42] Patil R, Kulshrestha A, Tikoo A, Fleetwood S, Katara G, Kolli B, et al. Identification of novel bisbenzimidazole derivatives as anticancer vacuolar (H⁺)-ATPase inhibitors. *Molecules*. 2017;**22**(9):pii: E1559. DOI: 10.3390/molecules22091559
- [43] Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. *Drug Development Research*. 1995;**34**:91-109. DOI: 10.1002/ddr.430340203
- [44] Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. *Molecular Cancer Therapeutics*. 2010;**9**(5):1451-1460. DOI: 10.1158/1535-7163.MCT-10-0106
- [45] Covell DG, Huang R, Wallqvist A. Anticancer medicines in development: Assessment of bioactivity profiles within the National Cancer

Institute anticancer screening data.
Molecular Cancer Therapeutics.
2007;**6**(8):2261-2270. DOI:
10.1158/1535-7163.MCT-06-0787

[46] Skehan P, Streng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. The Journal of the National Cancer Institute. 1990;**82**:1107-1112. DOI: 10.1093/jnci/82.13.1107

[47] Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. Journal of the National Cancer Institute. 1991;**11**:757-766. DOI: 10.1093/jnci/83.11.757

[48] Bartel K, Winzi M, Ulrich M, Koeberle A, Menche D, Werz O, et al. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling—a new option for HCC therapy. Oncotarget. 2017;**8**(6):9476-9487. DOI: 10.18632/oncotarget.14339

[49] Asleh R, Ward J, Levy NS, Safuri S, Aronson D, Levy AP. Haptoglobin genotype-dependent differences in macrophage lysosomal oxidative injury. The Journal of Biological Chemistry. 2014;**289**(23):16313-16325. DOI: 10.1074/jbc.M114.554212

[50] Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines. British Journal of Cancer. 1999 Dec;**81**(8):1328-1334. DOI: 10.1038/sj.bjc.6695007